Plain-English translation of NCT07492680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Solid Tumors research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called for people with advanced or spread-out solid tumors that have a specific genetic change (homozygous MTAP deletion). The study will test whether the medication works on its own or works better when combined with other cancer-fighting drugs or treatments.
Many cancer treatments don't work well for tumors with this particular genetic change. Researchers believe that targeting this specific genetic flaw with this new treatment could help people whose cancers have stopped responding to standard therapies.
You likely qualify if…
You likely don't qualify if…
Participants will receive , either alone (Part 1) or combined with other cancer medications or treatments (Part 2), depending on which group they join. The study involves multiple visits for blood tests, imaging scans, and health check-ups to monitor how well the medication works and track any side effects. The exact schedule and duration depend on your assigned treatment group and how your body responds.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States